Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Mielke

Showing results (61-70 of 126) with videos related to

Pageof 13
Sort By:
Lancet (London, England)|June 19, 2022
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialManali Kamdar, Scott R Solomon, Jon Arnason, et al.
American Journal of Hematology|June 10, 2024
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
Bone Marrow Transplantation|April 12, 2023
Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMTArnon Nagler, Myriam Labopin, Stephan Mielke, et al.
Journal of Hematology & Oncology|July 5, 2020
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donorsEolia Brissot, Myriam Labopin, Ian Moiseev, et al.
Bone Marrow Transplantation|December 25, 2021
Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patientsWolfgang A Bethge, Matthias Eyrich, Stephan Mielke, et al.
The Lancet. Haematology|January 6, 2024
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationOlaf Penack, Monia Marchetti, Mahmoud Aljurf, et al.
Ebiomedicine|July 15, 2023
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Blood|May 31, 2013
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signalingHugues de Lavallade, Ahmad Khoder, Melanie Hart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2025
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM StudyManali Kamdar, Scott R Solomon, Jon Arnason, et al.
Ebiomedicine|May 9, 2026
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunityPuran Chen, Peter Bergman, Ola Blennow, et al.
Pageof 13

Showing results (61-70 of 126) with videos related to

Sort By:
Pageof 13
Lancet (London, England)|June 19, 2022
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialManali Kamdar, Scott R Solomon, Jon Arnason, et al.
American Journal of Hematology|June 10, 2024
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
Bone Marrow Transplantation|April 12, 2023
Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMTArnon Nagler, Myriam Labopin, Stephan Mielke, et al.
Journal of Hematology & Oncology|July 5, 2020
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donorsEolia Brissot, Myriam Labopin, Ian Moiseev, et al.
Bone Marrow Transplantation|December 25, 2021
Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patientsWolfgang A Bethge, Matthias Eyrich, Stephan Mielke, et al.
The Lancet. Haematology|January 6, 2024
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationOlaf Penack, Monia Marchetti, Mahmoud Aljurf, et al.
Ebiomedicine|July 15, 2023
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Blood|May 31, 2013
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signalingHugues de Lavallade, Ahmad Khoder, Melanie Hart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2025
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM StudyManali Kamdar, Scott R Solomon, Jon Arnason, et al.
Ebiomedicine|May 9, 2026
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunityPuran Chen, Peter Bergman, Ola Blennow, et al.
Pageof 13